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Simian immunodeﬁciency virusMouse monoclonal antibodies with varying speciﬁcities against the Gag capsid of simian and human immu-
nodeﬁciency virus (SIV/HIV) were generated by immunizing mice with whole inactivated SIVagmTYO-1.
Monoclonal antibody AG3.0 showed the broadest reactivity recognizing the Gag capsid protein (p24–27)
and Gag precursors p38, p55, and p150 of HIV-1, HIV-2, SIVmac, and SIVagm. Using overlapping peptides,
the AG3.0 epitope was mapped in capsid to a sequence (SPRTLNA) conserved among HIV-1, HIV-2, SIVrcm,
SIVsm/mac, and SIVagm related viruses. Because of its broad cross-reactivity, AG3.0 was used to develop
an antigen capture assay with a lower detection limit of 100 pg/ml HIV-1 Gag p24. Interestingly, AG3.0
was found to have a faster binding on/off rate for SIVagmVer and SIVmac Gag than for SIVagmSab Gag,
possibly due to differences outside the SPRTLNA motif. In addition, the ribonucleic acid (RNA) coding for
AG3.0 was sequenced to facilitate the development of humanized monoclonal antibodies.
© 2011 Elsevier Inc. All rights reserved.Introduction
Since the discovery of HIV-1 and HIV-2 (Barre-Sinoussi et al.,
1983; Clavel et al., 1986; Gallo et al., 1983) an increasing number of
related SIVs have been isolated from nonhuman primates. Serological
evidence of SIV infection has been shown for at least 40 of the 69 dif-
ferent primate species in Africa and has been conﬁrmed by sequence
analysis in 32 (Aghokeng et al., 2010; Locatelli et al., 2008a). Com-
plete SIV genome sequences are available for 20 species (Liegeois
et al., 2009; Van Heuverswyn and Peeters, 2007; VandeWoude and
Apetrei, 2006). The primate lentiviruses can presently be classiﬁed
into 10 distinct lineages based upon phylogenetic relationships of
full-length sequences: 1) SIVcpz from chimpanzees (Pan troglodytes)
including HIV-1 and SIVgor from western gorillas (Gorilla gorilla)
(Santiago et al., 2003; Van Heuverswyn et al., 2006, 2007); 2) SIVsm
from sooty mangabeys (Cercocebus atys) including HIV-2 and SIVmacrs-Beer), eschrichtm@rki.de
id.nih.gov (V.M. Hirsch),
Jean Patterson (jpatters@sfbr.
rights reserved.from macaques (Macaca spp.) (Clavel et al., 1986; Franchini et al.,
1987; Hirsch et al., 1989); 3) SIVagm from African green monkeys
(members of the Chlorocebus aethiops superspecies) (Allan et al.,
1991; Hirsch et al., 1993b; Johnson et al., 1990); 4) SIVsyk from
Sykes' monkeys (Cercopithecus albogularis) (Hirsch et al., 1993a); 5)
SIVlho from L'Hoest monkeys (C. lhoesti) including SIVsun from sun-
tailed monkeys (C. solatus) and SIVmnd-1 from mandrills (Mandrillus
sphinx) (Beer et al., 1999; Hirsch et al., 1999; Tsujimoto et al., 1989);
6) SIVrcm from red-capped mangabeys (Cercocebus torquatus) in-
cluding SIVdrl from drills (Mandrillus leucophaeus), and SIVmnd-2
from mandrills (Beer et al., 2001; Hu et al., 2003); 7) SIVdeb from
DeBrazza monkeys (C. neglectus) (Bibollet-Ruche et al., 2004) includ-
ing SIVden from Dent's mona monkeys (C. mona denti) (Dazza et al.,
2005); 8) SIVgsn from greater spot-nosed monkeys (C. nictitans) in-
cluding SIVmon from mona monkeys (C. mona), and SIVmus-1 and
mus-2 from mustached monkeys (C. cephus) (Aghokeng et al., 2007;
Courgnaud et al., 2003a); 9) SIVtal from talapoinmonkeys (Miopithecus
ogouensis) (Liegeois et al., 2006); and 10) SIVcol from Colobus monkeys
(Colobus guereza) (Courgnaud et al., 2001). Some lineages, such as
SIVcpz, are presumed to be the result of recombination between other
lineages (SIVrcm and SIVgsn) (Bailes et al., 2003). Smaller fragments
from other SIV-infected African primate species have also been se-
quenced and may indicate the existence of either separate lineages
403B.E. Sanders-Beer et al. / Virology 422 (2012) 402–412[SIVbkm from blackmangabeys (Lophocebus aterrimus) (Takemura et al.,
2005), SIV-ASC-Qu from Schmidt's guenon (C. ascanius schmidti)
(Verschoor et al., 2004)], or reveal genetic relationships to the lineages
mentioned above (SIVwrc, SIVolc to the SIVlho lineage) (Courgnaud
et al., 2003b; Locatelli et al., 2008b).
For diagnostic purposes, monoclonal antibodies (mAbs) are useful
to characterize immunodominant antigenic sites or functional do-
mains on viral components. In addition, they are needed to develop
a variety of virological assays, most importantly antigen capture as-
says for HIV and SIV. Moreover, measurements of SIV antigen in
cells and tissues, such as kinetic studies, virus titrations, immunohis-
tochemistry, and neutralization tests, require a reliable and fast meth-
od for measuring virus production. HIV/SIV capsid protein (p24–27)
is the most abundant protein produced during virus replication
(Veronese et al., 1988) and is found both inside infected cells and in
virus particles released by infected cells forming a protective shell
for viral RNA. Antigen-capture enzyme-linked immunosorbent assays
(ELISAs) that determine the p24–27 amount in plasma or cell culture
samples are frequently used in HIV/SIV research as endpoint for neu-
tralization as well as antiviral assays. Besides antigen capture ELISA,
there are other assays available for quantitating HIV/SIV in body or
tissue culture ﬂuids, such as viral RNA quantiﬁcation or the measure-
ments of reverse transcriptase (RT) activity. Compared to the antigen
capture ELISA, those other methods have both advantages and disad-
vantages. The measurement of viral RNA is highly sensitive, but re-
quires exact knowledge of the underlying sequence and necessitates
storage of the samples at very low temperatures to prevent degrada-
tion of the viral RNA. On the other hand, quantiﬁcation of RT enzyme
activity is less sensitive than that of p24–27 protein determination
because Gag is the major structural protein and is present at about
5000 copies per virion (Briggs et al., 2004). In addition, inappropriate
sample storage can also interfere with sensitivity of RT quantitation
since enzymes are more sensitive to temperature changes than are
proteins. Measurement of RT activity is also not speciﬁc for HIV/SIV
since all retroviruses code for this enzyme. Compared to viral RNA
and RT, p24–27 is a fairly stable protein, is speciﬁc for and also anti-
genically cross-reactive with a wide variety of HIVs and SIVs, and
large numbers of samples can be processed on a single ELISA plate.
Antigen capture assays for HIV and SIV are commercially available,
but are expensive and can have limited utility for detecting a wide
range of SIV and HIV types. Neutralization tests or virus titrations
usually require processing of high quantities of samples, and thus it
is desirable to develop cost-effective in-house assays that incorporate
monoclonal antibodies broadly reactive to SIV and HIV. Furthermore,
determinations can be made by detecting p24–27 expression in
infected cells by means of immunohistochemical staining methodolo-
gies or western blot/radioimmunoprecipitation.
In this study, the generation and characterization of several mouse
monoclonal antibodies against SIVagm are presented; one antibody
(AG3.0) was broadly reactive to HIV-1, HIV-2/SIVsm/SIVmac and
SIVagmbywestern blotting and radioimmunoprecipitation. The epitope
recognized by AG3.0 mapped to a 7-mer peptide within the N-terminal
portion of the Gag capsid, a highly conserved region among primate len-
tiviruses (HIV-1, HIV-2/SIVmac, SIVagm, and SIVrcm). The antibodywas
donated to the NIH AIDS Research and Reference Reagent Program
(ARRRP; www.aidsreagent.org, catalog number 4121) and has been
used in experimental studies by a number of investigators (Leblanc
et al., 2008; Potash et al., 1998; Sakuma et al., 2007; Schiavoni et al.,
2004). As a next step, a p24–27 antigen capture assay comparable in
sensitivity to immunostaining of infected cells was developed. Testing
of representative virus strains from six primate lentiviral lineages by
antigen capture assay revealed the broad spectrum binding of mAb
AG3.0 in recognizing p24–27 species from HIV-1, HIV-2, SIVmac,
SIVagm, and SIVrcm, but not SIVlho, SIVsun, and SIVsyk. The lower
limit of quantitation of the assay was determined to be 100 pg/ml p24
Gag. Subsequently, both the heavy and light chains of AG3.0 weresequenced and annotated to facilitate humanized anti-p24 antibody
development.Results
Generation of three monoclonal antibodies that react with SIV Gag
Mousemonoclonal antibodies againstwhole disrupted SIVagmTYO-1
were produced using a standard mouse-cell hybridoma technique.
Hybridomas were screened for reactivity to SIVagmTYO-1 by whole
virus ELISA. The speciﬁcity of positive hybridomas was further evaluated
by immunoblotting and three hybridomas were selected, whose super-
natants detected SIV Gag p27. The hybridomas were cloned by single
cell endpoint dilution and were designated AG3.0, AG5.0, and AG6.0.
All three monoclonal antibodies were determined to be of the immuno-
globulin G type 1 (IgG1) isotype. As shown in Fig. 1, AG3.0 showed the
broadest reactivity by immunoblotting and detected Gag p24–27 from
all four SIVagm isolates (ver, gri, sab, tan) as well as from SIVmac, HIV-
2 and HIV-1, AG5.0 reacted with all SIVagm subtypes, and HIV-1 and
HIV-2 Gag proteins, but not with SIVmac Gag while AG6.0 only reacted
with SIVagmGag from vervet and tantalusmonkeys. Additionally, radio-
immunoprecipitation analysis (RIPA) was performed with both cell and
virus lysates (Fig. 2). RIPA differs from immunoblot analysis in that radi-
olabeled native proteins in solution react with antibody whereas in
immunoblotting viral proteins aremostly denatured due to the presence
of sodiumdodecyl sulfate (SDS). Themonoclonal antibodyAG3.0 reacted
with p24–27 and the Gag precursor proteins p38, p55, and p160 from
SIV- and HIV-infected cell lysates. Monoclonal antibody AG1.0, recogniz-
ing gp120 from SIVagm and SIVmac, and antibody AG4.0, an anti-cellular
antibody, served as controls. Overall, AG3.0 was the most broadly cross-
reacting monoclonal antibody recognizing the Gag capsid and precursor
products of at least three different primate lentivirus lineages.AG3.0 reacts with a 7-mer Gag peptide that is conserved between several
lentivirus lineages
In order to determine the epitope recognized by AG3.0, we initially
used a series of overlapping Gag p26 peptides provided by the EU AIDS
Vaccine Integrated Project's Programme EVA for epitope mapping.
Twenty-two 20-mer peptides with a 10 amino acid overlap were tested
for reactivity with AG3.0 (Table 1). AG3.0 reacted with a single peptide
spanning amino acid 11 to 30 from SIVmac251Gag (HLPLSPRTLNAWVK
LIEEKK), but not with any of the surrounding peptides, indicating that
the minimal AG3.0 epitope is located in the center of the peptide at the
N-terminus of Gag capsid. Subsequent ﬁne mapping using 13-mers with
12-mer overlaps covering the sequence GGNYVHLPLSPRTLNAWVK
LIEEKK (SIVmac251Gag aa 141–165) revealed a minimal epitope with
the sequence SPRTLNA. This was concluded from the fact that two of
the peptides missing one amino acid at the beginning or the end of the
epitope (NYVHLPLSPRTLN and PRTLNAVWKLIEE, Fig. 3) were not recog-
nized by AG3.0. A sequence alignment between representatives of ten
primate lentiviral lineages is shown in Table 2A and demonstrates that
the epitope SPRTLNA is conserved between most SIVcpz, SIVsm, SIVagm,
and SIVrcm related viruses. Only theHIV-1 Ngroup and SIVcpz-ANTdiffer
by one amino acid at the N-terminus (threonine instead of serine). This
peptide also differs in the following viruses (conserved amino
acids underlined): SIVlho (SPRTIQT), SIVsun (SPRTVQT), SIVmndGB1
(SPRIIQT), SIVcol (SPRTLGA), SIVsyk (PVRTLKT), SIVmon (EPRLLKT),
SIVmus-1 (NARILKT), SIVmus-2 (SPRLLKT), SIVgsn (NSRILKT), SIVdeb
(SPRIVKT), SIVden (STRVLKT), and SIVtal (SPRLLKT). Generally, the
N-terminus of the epitope was more conserved than the C-terminus
among the ten primate lentivirus lineages. The only conserved amino
acid among all simian and human immunodeﬁciency viruses described
so far was arginine in position 3.
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Fig. 1.Western blot analysis. Reactivity of different Gag-speciﬁc monoclonal antibodies against various puriﬁed isolates of SIV and HIV in western blot performed as described in the
Materials and methods. A: Isolates from the four subspecies of African green monkeys. B: Isolates from rhesus macaques and humans. Neg: Negative control sera from uninfected
individuals of the relevant species. Pos: Positive polyclonal control sera from individuals of the relevant species infected with the corresponding virus.
404 B.E. Sanders-Beer et al. / Virology 422 (2012) 402–412AG3.0 antigen capture assay for detecting virus from three major lentiviral
lineages
Antigen capture assays are useful tools for identifying and quantify-
ing plasma virus levels in infected monkeys and for measuring virus
growth in tissue culture. Since AG3.0 recognized three major lineages
commonly used in AIDS research, a broadly reactive antigen capture
assay was developed, which could detect a wide variety of HIV/SIV cap-
sid antigens. In order to generate pure antibody material, IgG was puri-
ﬁed from hybridoma supernatants using Protein G sepharose columns,
and the optimal AG3.0 IgG concentration was determined as follows:
An ELISA plate coated with two-fold dilutions of AG3.0 was reacted
with 0.2% Tween20 disrupted SIVagmVER.DE.x.AGM3 supernatant.
Captured protein was detected using a polyclonal antibody from an
SIV-infected monkey followed by goat anti-human immunoglobulinM
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Fig. 2. Radioimmunoprecipitation analysis. Binding of the AG3.0 monoclonal antibody to rad
clonal antibodies AG1.0, recognizing gp120 from SIVagm and SIVmac, and AG4.0, recognizin
and gp120 are marked with a box.G-peroxidase conjugate and substrate. The optimal IgG concentration
for coating ELISA plates was determined as 0.675 μg/well.
Next, virus supernatant from three different primate lentivirus lin-
eages (HIV-1, HIV-2/SIVsm, and SIVagm) as well the chimeric virus
SHIV 89.6 (HIV-1 89.6 env, tat, rev, vpu in an SIVmac239 backbone)
was serially titrated in C8166 or Molt4clone8 cells (Table 3) and the
amount of p24–27 content determined in an AG3.0 antigen capture
assay. Wells were considered positive if the optical density exceeded
the mean of the negative controls plus three times the standard devi-
ation. In parallel, the virus-exposed cells were subjected to HIV/SIV-
speciﬁc immunostaining. The mean tissue culture infectious dose
(TCID50) was calculated using both endpoints, i.e., antigen capture
assay optical densities of supernatants and HIV/SIV-speciﬁc immu-
nostaining of cells. As shown in Table 3, the results of the antigen cap-
ture assay matched the results of the cellular immunostaining withinA
G
1.
0
A
G
4.
0
A
G
3.
0
A
G
1.
0
A
G
4.
0
A
G
3.
0
A
G
1.
0
A
G
4.
0
A
G
3.
0
A
G
1.
0
ac HIV-2 HIV-1 Tyo-1
gp120
p55
p24
iolabeled Gag protein from cells infected with various SIV and HIV isolates. The mono-
g a cell protein, were included as controls. Bands showing reactivity with p24–27, p55,
Table 1
Rough epitope mapping of AG3.0.
SIVmac251 Gag Capsid Sequence
001 PVQQIGGNYV HLPLSPRTLN AWVKLIEEKK FGAEVVPGFQ ALSEGCTPYD
051 INQMLNCVGD HQAAMQIIRD IINEEAADWD LQHPQPAPQQ GQLREPSGSD
101 IAGTTSSVDE QIQWMYRQQN PIPVGNIYRR WIQLGLQKCV RMYNPTNILD
151 VKQGPKEPFQ SYVDRFYKSL RAEQTDAAVK NWMTQTLLIQ NANPDCKLVL
201 KLGLVNPTLE EMLTACQGVG GPGQKARL
Peptidea Sequence Mean OD StDev
1 01–20 0.01 0.00
2 11–30 0.37 0.05
3 21–40 0.01 0.00
4 31–50 0.01 0.00
5 41–60 0.01 0.00
6 51–70 0.01 0.00
7 61–80 0.01 0.00
8 71–90 0.01 0.00
9 81–100 0.01 0.00
10 91–110 0.01 0.00
11 101–120 0.01 0.00
12 111–130 0.01 0.00
13 121–140 0.01 0.00
14 131–150 0.01 0.00
15 141–160 0.01 0.00
16 151–170 0.01 0.00
17 161–180 0.01 0.00
18 171–190 0.01 0.00
19 181–200 0.01 0.00
20 191–210 0.01 0.00
21 201–220 0.01 0.00
22 211–228 0.01 0.00
a Peptides were ordered from the European AIDS Reagent Programme, reference
ARP714.1-22; peptides 15, 16, and 18 have an additional N-terminal cysteine.
GGNYVHLPLSPRT1
GNYVHLPLSPRTL2
NYVHLPLSPRTLN3
YVHLPLSPRTLNA4
VHLPLSPRTLNAW5
HLPLSPRTLNAWV6
LPLSPRTLNAWVK7
PLSPRTLNAWVKL8
LSPRTLNAWVKLI9
SPRTLNAWVKLIE10
PRTLNAWVKLIEE11
RTLNAWVKLIEEK12
TLNAWVKLIEEKK13
A B
Fig. 3. Fine epitope mapping of SIVmac Gag. Binding of the AG3.0 monoclonal antibody
to synthetic peptides spanning the putative epitope in Gag within the sequence
GGNYVHLPLSPRTLNAWVKLIEEKK (SIVmac251 Gag aa 141–165). The peptides, 13-mers
with a 12 amino acid overlap were synthesized directly onto a cellulose membrane and
binding of AG3.0 visualized by enhanced chemiluminescence (A). A density plot along
the membrane was carried out to aid analysis or reactivity (B).
405B.E. Sanders-Beer et al. / Virology 422 (2012) 402–412the expected range of assay variability. These results suggested that
the antigen capture assay is equivalent to immunostaining as end-
point analysis for virus titrations and virus neutralization assays.
Third, the reactivity of AG3.0 to HIVs and SIVs from ﬁve primate
lentivirus lineages was tested by antigen capture ELISA. As shown in
Fig. 4, the AG3.0-based antigen capture assay was able to detect Gag
capsid from HIV-1, HIV-2, SIVmac, SIVagm, and SIVrcm, but not
from SIVsun, SIVlho, and SIVsyk. For this experiment, two-fold dilu-
tions of virus supernatants were assayed, and the optical densities
decreased proportionally to the virus dilutions. At about a 100-fold
dilution of supernatant, the signal became undetectable. Overall, the
cross-reactivity of the AG3.0 antibody was consistent with the
amino acid conservation of the Gag epitope (see Table 2A). As
described above and shown in Table 2A, the epitope SPRTLNA is
mostly conserved among the HIV-1/SIVcpz, HIV-2/SIVsmm, and
SIVagm lineages, and SIVrcm. In SIVsyk, SIVsun, and SIVlho, it differs
by 3–4 amino acids, which prohibit binding to the monoclonal anti-
body. Viruses from the SIVdeb, SIVgsn/mon/mus, and SIVtal lineages
were not tested, but the epitope differs by 2–5 amino acids from
SPRTLNA, and it would be unlikely that the AG3.0 antibody cross-
reacts with Gag from these viruses. In contrast, the conservation of the
epitope in SIVdrl and SIVmnd-2, which are phylogenetically related to
SIVrcm. likely predicts cross-reactivity.
Afﬁnity determination of the interaction between AG3.0 and Gag proteins
from SIVagm and SIVmac
Surface plasmon resonance (SPR) technology was used to evaluate
the binding afﬁnity of the monoclonal antibody AG3.0 to different SIV
Gag proteins. Although the calculated maximal response (Rmax) was
100 response units (RU), the observed Rmax was more than double,
likely due to multimerization of the Gag protein (data not shown).
The highest afﬁnity was obtained using SIVagmVer (3.7 nM) while
the afﬁnities for SIVmac Gag and SIVagmSab Gag were lower but sim-
ilar with 20 nM and 35 nM, respectively (Fig. 5A). Interestingly, whilethe dissociation of SIVagmVer Gag and SIVmac Gag was fairly rapid,
the binding between the AG3.0 mAb and SIVagmSab Gag was found
to be very stable, with very little dissociation detectable (Fig. 5B).
Sequencing of the AG3.0 antigen binding site
cDNAs generated from RNA coding for the variable fragments of the
AG3.0 heavy and light chains were sequenced and analyzed using the
Vbase2 application (http://www.vbase2.org) to identify the conserved
framework regions (FR1-FR4) andvariable complementarity determining
regions (CDR1–CDR3) according to the International ImMunoGeneTics
(IMGT) nomenclature (Fig. 6). The three variable heavy chain regions
were found to consist of 8, 8 and 16 amino acids for CDR1, CDR2 and
CDR3, respectively, whereas the light chain had corresponding CDR
lengths of 11, 3, and 9.
Discussion
Monoclonal antibodies against SIVagm Gag p27 were developed to
allow the Gag capsid expression in African greenmonkeys and in patho-
genic macaque models of SIV infection to be compared. Gag is an impor-
tant structural protein and is often referred to as a precursor because it is
subject to cleavage by the viral protease, which yields the internal struc-
tural proteins of the mature virion (Freed, 1998; Swanstrom and Wills,
1997; Vogt, 1997; Wills and Craven, 1991). Three of the Gag cleavage
products, matrix, capsid, and nucleocapsid, are common to all retrovi-
ruses and are always arranged in this order within the Gag precursor,
with matrix being at the N-terminus. Additionally, the Gag precursors
Table 2A
Alignment of Gag capsid N-terminus (B.FR.83.HXB2_LAI_IIIB aa 160–176).
Table 3
Comparison of TCID50/ml calculations using AG3.0 antigen capture assay or HIV/SIV-
speciﬁc immunostaining.
Virus Titrated in Log10 Titer (TCID50/ml)
Endpoint analysis
AG3.0 antigen capture
assay of supernatants
HIV/SIV-speciﬁc
immunostaining
of cells
SHIV 89.6 C8166 cells 5.52 5.64
HIV-2 UC3 C8166 cells 4.99 4.79
SIVsmmPBj 1.9 C8166 cells 4.87 5.04
SIVagm3 C8166 cells 6.54 6.48
SIVagm3 Molt4clone8 cells 4.81 4.63
SIVmac 32H C8166 cells 6.71 6.71
HIV-1 LAI C8166 cells 4.69 4.39
406 B.E. Sanders-Beer et al. / Virology 422 (2012) 402–412of HIV and SIV possess a C-terminal domain termed p6 that is unique to
primate lentiviruses, as well as two “spacer” regions that separate capsid
from nucleocapsid, and nucleocapsid from p6 (Henderson et al., 1992;
Mervis et al., 1988).
Capsid, which directly follows matrix in the Gag precursor, has cru-
cial roles in particle assembly and after entry into a new target cell.
However, the function of capsid in the early phase of the replication
cycle is not well understood. In the mature virion, capsid forms the
shell of the core, which is occasionally tubular but most often conical,
a feature that distinguishes lentiviruses, such as HIV-1, from most
other retroviruses (Gelderblom, 1991). Capsid has two predominantly
α-helical domains that are connected through a ﬂexible linker regionTable 2B
Alignment of amino acid sequence adjacent to SPRTLNA.
VER . KE . x . TYO1 AQQQGNAWVHVPLSPRTLNAWVKAVEEKKFGAEIVPM
VER . DE . x . AGM3 --------I--SPRTLNA----------------
SAB . SN . x . SAB1C IVSVN-Q---Q-SPRTLNA---VI-----S--V---
MAC . US . x . 239 V--I-GNY--L-SPRTLNA---LI--------V--G(Gamble et al., 1997; Gitti et al., 1996;Momany et al., 1996) and has dif-
ferent roles in virus morphogenesis. The N-terminal domain, which
comprises two thirds of HIV-1 capsid, is required for the formation of
the mature core but is dispensable for the assembly of immature virus
particles (Borsetti et al., 1998; Dorfman et al., 1994; Reicin et al., 1995,
1996; Srinivasakumar et al., 1995;Wang and Barklis, 1993). In contrast,
the C-terminal capsid domain is crucial both for particle assembly and
for core formation (Dorfman et al., 1994; Mammano et al., 1994;
McDermott et al., 1996; Reicin et al., 1995). The N-terminal domain of
HIV-1 capsid interacts with the human peptidyl-prolyl cis-trans isomer-
ase cyclophilin A (CyPA), which leads to the speciﬁc incorporation of this
ubiquitous cytosolic host protein into virions (Franke et al., 1994; Luban
et al., 1993; Thali et al., 1994). This feature is unique for HIV-1 and absent
in other primate lentiviruses andHIV-2. Based on the regular appearance
of the synthetic cones, Sundquist et al. propose that retroviral cores are
composed of hexagonal lattices that are closed through the incorporation
of a total of 12 pentagons (Ganser et al., 2003).
In the study presented here, three monoclonal antibodies against
SIVagm from the vervet subspecies (SIVagmTYO-1) were generated
and characterized. AG6.0 cross-reacted with two subspecies of African
greenmonkeys (vervet and tantalus), whereas AG5.0 showed a broader
cross-reactivity, reacting with SIVagm Gag p26 from vervet, grivet,
sabaeus, and tantalus, HIV-1 and HIV-2. Interestingly, although HIV-2
and SIVmac have similar ancestries, having both arisen by transmission
from sooty mangabeys (SIVsm), only the p26 from HIV-2ST was recog-
nized. AG3.0 showed the broadest cross-reactivity and recognized not
only the SIVagm lineage, but also members of the HIV-2 lineage (HIV-
2, SIVmac), HIV-1 lineage, and SIVrcm. In addition, AG3.0 reacted with
the Gag precursors p55 and p38 and the Gag-Pol precursor in infected
cell lysates. This broadly cross-reactive antibody (AG3.0) is available
from the NIH ARRRP as “Monoclonal antibody to HIV-1 p24” under cat-
alog no. 4121 (Simm et al., 1995). In addition, the AG3.0 producing hy-
bridoma cells are also available. A number of monoclonal antibodies
speciﬁc for HIV and SIV Gag are deposited in the NIH ARRRP but, with
the exception of AG3.0, none reacts with SIVagm or is broadly cross-
reactive with SIV and HIV. So far, only Otteken et al. (1992) successfully
produced monoclonal antibodies to SIVagm Gag p27 (strain TYO-7).
However, these monoclonal antibodies (1.17.3, 1A7 and 1F6) are pri-
marily type-speciﬁc, reacting with only certain types of SIVagm and
theHIV-2 lineage, but notwith HIV-1 or SIVmndGB1. Thesemonoclonal
antibodies mapped to a peptide spanning amino acids 152 to 172 in
SIVmac251, which is conserved in the HIV-2 lineage, but not in
SIVagmTYO-1, HIV-1 IIIB, and SIVmndGB1. One particular monoclonal
antibody, FM18, generated against SIVmac, also reacted with SIVagm,
but not with HIV-1 (Lairmore et al., 1993). Since this antibody has not
been mapped, the full extent of cross-reactivity is unknown. However,
our broadest reactive monoclonal antibody, AG3.0, is able to detect
p24–27 from all of the main primate lentivirus lineages including HIV-
1, SIVmac/HIV-2, SIVagm, and SIVrcm.
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Fig. 4. Antigen capture ELISA using various isolates. Supernatants from cells infected with various isolates of SIV and HIV were tested at different dilutions for reactivity in the AG3.0
based antigen capture assay as described in the material and methods.
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by AG3.0 to be SPRTLNA (Table 1, Fig. 3). This epitope is conserved
throughout the HIV-1 (including SIVrcm), HIV-2 and SIVagm lineages,
and is partially conserved throughout the other SIV lineages (SIVlho,
SIVsyk, SIVcol, SIVdeb, SIVtal, SIVgsn), although it is completely absent
in non-primate lentiviruses. However, despite this partial conservation,
AG3.0 does not recognize SIVlho, SIVsun, or SIVsyk Gag, indirectly con-
ﬁrming theminimal epitope needed for binding (Fig. 4). Von Schwedler
et al. (2003) showed that viruses with a mutated arginine and aspara-
gine in the SPRTLNA motif failed to form a cone-shaped core and were
not infectious, indirectly demonstrating the importance of this epitope
for viral assembly. The Los Alamos Immunology database contains 21
HIV-1 cytotoxic T-lymphocyte (CTL) epitopes restricted by HLA-A, -B,
and -C haplotypes spanning the SPRTLNA peptide (http://www.hiv.
lanl.gov/content/immunology/ctl_search) suggesting immunogenic
dominance of the region. For example, a dominant CTL epitope ISPRTL-
NAWhas beendetected inHIV-1 positive individuals having the protec-
tive haplotype HLA B*5701 (Bailey et al., 2006), which is found in a very
high frequency in HIV-1 infected non-progressors (11/13 or 85% versus
19/200 or 9.5% of progressors). Non-progressors tended to have an im-
mune response that was highly focused on four p24 epitopes that were
presented by B*5701, ISPRTLNAW, KAFSPEVIPMF, TSTLQEQIGW, and
QASQEVKNW (Migueles and Connors, 2001). THE SPRTLNA epitope is
also part of three human CD4+ T helper cell HIV-1 epitopes and two
mouse monoclonal antibody HIV-1 epitopes (AISPRTLNAW for the F5-2
antibody and VHQAISPRTLNAWVK for the ID8F6 antibody) (http://
www.hiv.lanl.gov/content/immunology/ctl_search).
After mapping the AG3.0 epitope, we sought to develop an antigen
capture ELISA using the AG3.0 monoclonal antibody since it showed
the broadest cross-reactivity against HIV/SIV (Binninger-Schinzelet al., 2008). Currently, there is only one commercially available anti-
gen capture assay that cross-reacts with SIVmac, SIVagm, SIVdrl, and
SIVmnd-2 (from ZeptoMetrix Corp.) (Hu et al., 2003; Pandrea et al.,
2006). However this assay is expensive and the epitope recognized
by themonoclonal antibody that forms the basis of the test is not public
knowledge. Therefore, the degree of cross-reactivity with different HIV/
SIV isolates can only be determined empirically. Most in-house antigen
capture assays using monoclonal antibodies developed to date are ei-
ther optimized for the HIV-1/SIVcpz or HIV-2/SIVmac/SIVsm lineage
(Lohman et al., 1991; Thorstensson et al., 1991; Wehrly and Chesebro,
1997). Only one assay, based on a polyclonal sandwich system, was
also able to detect SIVmnd to an appreciable degree (Beirnaert et al.,
1998). Our AG3.0 in-house antigen capture assay had a lower limit of
detection of 100 pg/ml, comparable to that of Zeptometrix's SIV p27 an-
tigen ELISA (62.5 pg/ml). Optimization of the reagents used in the
AG3.0 antigen capture assay should further enhance its sensitivity.
The binding afﬁnity of AG3.0 to SIVagm and SIVmac Gag puriﬁed
from native virus was determined using SPR technology. SIVagmSab2
Gag was found to bind slowly to AG3.0, whereas the overall binding
afﬁnity was more similar to SIVmac than to SIVagmVer. In addition,
the dissociation curve was markedly different from both SIVmac and
SIVagmVer and indicated a very stable complex between SIVagmSab2
and AG3.0. The same results were obtained with two different Gag con-
centrations (data not shown). Although all three Gag proteins share the
same minimal epitope, the binding structures could be inﬂuenced by
residues ﬂanking the SPRTLNA epitope, resulting in different tertiary
structures of the whole Gag protein and therefore different binding af-
ﬁnities to AG3.0 (Table 2B). To our knowledge, crystallization of the
SIV capsid protein, needed to address this hypothesis, has not yet been
achieved. Finally, the AG3.0 monoclonal antibody RNA was sequenced
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Fig. 5. Surface plasmon resonance (SPR) analysis. A: Binding afﬁnity proﬁles of Gag proteins derived from different SIVs to AG3.0 measured by BIAcore as described in the materials
and methods. Sensor chips coated in AG3.0 were exposed to puriﬁed preparations of the different Gag proteins at various concentrations. Binding was measured as a change in RU at
equilibrium. The apparent kD values were determined using the BiaEvaluation software (GE Healthcare). B: Dissociation curves for the different Gag proteins (1.5 μg/ml) using an
injection period of 1080 s, a dissociation time of 3000 s, and a ﬂow rate of 5 μl/min.
408 B.E. Sanders-Beer et al. / Virology 422 (2012) 402–412and annotated to facilitate creating a human- ormonkey-adaptedmono-
clonal antibody speciﬁc for the SPRTLNA epitope. This would allow anti-
capsid antibodies for modulation of SIV/HIV infection to be evaluated.
In summary, we generated three mouse monoclonal antibodies
against SIVagmTYO-1 (Ver) Gag capsid, each with varying degrees of
cross-reactivity to SIV/HIV. The broadest cross-reactivity was found with
AG3.0, which recognized p24–27 from the threemajor primate lentivirus
lineages (HIV-1/SIVcpz/SIVrcm, HIV-2/SIVsm/SIVmac, and SIVagm) and
mapped to a conserved 7 amino acid motif in Gag, SPRTLNA (aa
156–162 of SIVagmTYO-1 Gag). An antigen capture assay was devel-
oped, which could detect as little as 100 pg/ml of p24 Gag.
Materials and methods
Monoclonal antibody production
BALB/c mice were immunized by intraperitoneal injection of 10 μg
sucrose gradient puriﬁed SIVagm(TYO-1) in phosphate buffered sa-
line (days 0 and 21) in addition to 10 μg of 1% Triton X-100-treatedSIVagm(TYO-1) (day 14). The mice were sacriﬁced at day 24 and the
spleen removed for fusion of splenic cells with SP-2 mouse myeloma
cells. The hybridomas were grown in 96-well plates using DMEM (Life
Technologies) supplemented with 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 20% fetal bovine serum, with
10 mM hypoxanthine and 2 μg/ml of azaserine (Sigma-Aldrich) for
selection. Supernatant ﬂuid (100 μl) from each well showing visible
hybridoma growth was evaluated for reactivity to SIVagm(TYO-1) by
whole virus ELISA and positive samples screened by western blotting.
Clones of interest were subcloned twice. The isotype of each monoclo-
nal antibody was determined with the Sigma ImmunoType™ Kit
according to the manufacturer's instructions.
Virus puriﬁcation
Culture supernatant ﬂuid (5–10 l) from SIVagm(TYO-1) infected
MOLT4clone8 cells was concentrated 50–100 fold with a Minitan ul-
traﬁltration system (Millipore) containing 5 ﬁlters with a 300,000
molecular weight pore size. The retentate (50–100 ml) was layered
Fig. 6. Amino acid sequences of the heavy and light chains of the AG3.0 monoclonal an-
tibody. The four conserved framework regions (FR1-FR4) and the three hypervariable
complementarity determining regions (CDR1–CDR3) are displayed according to the
IMGT nomenclature (Lefranc, 2007). Unoccupied amino acid positions are marked
with an en dash (–). X=positions in the conserved FR1 region of the heavy chain, at
which the identity of the amino acid could not be unequivocally determined from
the sequence.
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covered from the interface after centrifugation for 2 h at 71,500×g.
The virus fraction was diluted 2× with TEN (0.05 M Tris–HCl pH 7.2,
0.15 M NaCl, and 1 mM Ethylenediaminetetraacetic acid (EDTA)),
layered over a 20–70% continuous sucrose gradient and centrifuged
overnight at 71,500×g. One milliliter fractions were assessed with a
refractometer, the virus fractions (1.16–1.18 g/cm3) diluted 5-fold with
TEN buffer, and the virus was pelleted by centrifugation at 71,500×g
for 2 h at 4 °C. The virus pellets were resuspended in a volume of
1.0 ml phosphate buffered saline (PBS), and the protein concentration
was determined using the Bio-Rad Protein Assay according to themanu-
facturer's instructions (Bio-Rad Life Sciences). The virus was further an-
alyzed for purity by SDS-PAGE with the protein bands visualized by
immunoblotting.Whole virus ELISA
Puriﬁed SIVagm(TYO-1) was diluted to 2 μg/ml in borate buffered
saline (BBS) and used to coat Immulon II plates (Dynex Technologies
Inc., Chantilly, VA) overnight at 4 °C. Wells were blocked with 10% nor-
mal goat serum in BBS for 30 min at 37 °C, and the plates washed 3
times with 1% Tween20 in phosphate buffered saline. One hundredmi-
croliters of hybridoma supernatant ﬂuidwas then added, and the plates
were incubated for 60 min at 37 °C, andwashed three times prior to ad-
dition of biotinylated anti-mouse antibody. Binding was determined
colorimetrically by incubation with streptavidin-horseradish peroxi-
dase (Amersham) before washing and developing with 2,2′-Azinobis
(3-ethylbenzthiazoline-sulfonic acid) (ABTS).Cells and viruses
All human CD4+ T cell lines were maintained in complete medium
consisting of RPMI 1640 supplemented with 15% fetal bovine serum
(Life Technologies), HEPES, 2 mM L-glutamine, 50 μg/ml streptomycin
and 50 U/ml of penicillin. SIVagm strains VER.KE.x.TYO1, GRI_677,
SAB.SN.x.SAB1C, SAB.SN.x.SAB2, SAB.SN.x.SAB4, TAN.UG.x.TAN1, and
HIV-2ST (Broussard et al., 2001; Fomsgaard et al., 1991; Jin et al.,
1994; Kumar et al., 1990; Shibata et al., 1990; Soares et al., 1997)
were grown in Molt4clone8 cells, SIVagm(Ver-1) (Jin et al., 1994) in
SupT1 cells, SIVmac251 in Hut78 cells, and HIV-1/IIIB in Molt3 cells.
Western blot analysis
Western blotting was performed as previously described (Allan
et al., 1991). Virus in culture supernatants taken from infected cell
lines at 48–72 h was puriﬁed through a 20% sucrose cushion, separat-
ed by SDS-polyacrylamide gel electrophoresis, and then blotted onto
nitrocellulose sheets. The nitrocellulose paper was blocked with 3% bo-
vine serum albumin and subsequently incubated with a 1:8 dilution of
monoclonal antibody supernatant ﬂuid or a 1:80 dilution of seroposi-
tive and seronegative controls. Viral proteins were detected using the
streptavidin–biotin system (Amersham) with diaminobenzidine as
the substrate for color development.
Radioimmunoprecipitation analysis
Radioimmunoprecipitation analysis (RIPA) of virus lysates was
conducted as described previously (Allan et al., 1992). Infected
cells were metabolically labeled for 16 h with 35-S cysteine and
methionine (Translabel, ICN Biomedicals, Inc., Costa Mesa, CA) at
1 mCi/107 cells in cysteine–methionine free RPMI 1640 with 15%
FBS. The cells were resuspended in RIPA buffer (0.08 M Tris–HCl
pH 7.4, 0.15 M NaCl) containing 0.1% SDS, 1% Triton X-100, and 1%
deoxycholate with protease inhibitors (1.0 mM phenylmethyl sulfo-
nyl ﬂuoride (Pierce) and 2 μg/ml of leupeptin (Sigma-Aldrich)) and
centrifuged at 100,000×g to remove protein aggregates. Proteins
were then immunoprecipitated with monoclonal antibodies bound to
protein A sepharose. The complexes were washed 5 times with com-
plete RIPA lysing buffer, the viral proteins solubilized by resuspension
in electrophoresis sample buffer (0.08 M Tris–HCl pH 6.8, 2% SDS,
0.1 M dithiothreitol, 10% glycerol, and 1 mg/ml of bromophenol blue),
and the viral proteins separated by 11.3% SDS-PAGE. Proteins were
visualized by impregnating the gel with EnHance (DuPont NEN, Boston,
MA) before drying and exposure to Kodak SB5 radiographic ﬁlm
(Eastman Kodak).
Epitope mapping
A panel of overlapping SIVmac Gag synthetic peptides (20-mers,
10 overlap; kindly provided by the European AIDS Reagent Pro-
gramme, reference ARP714.1-22) was used in a standard ELISA for
rough epitope mapping of the AG3.0 monoclonal antibody. For ﬁne
epitope mapping, a series of 13-mer synthetic peptides with an over-
lap of 12 aa covering the sequence GGNYVHLPLSPRTLNAWVKLIEEKK
(SIVmac251 Gag 141–165) was synthesized directly onto a cellulose
membrane (Jerini Bio Tools GmbH, Berlin, Germany). Brieﬂy, the mem-
brane was washed 3 times in Tris-buffered saline containing 0.05%
Tween20 (T-TBS) and blocked overnight at 4 °C with T-TBS plus 2%
milk powder and 10% sucrose (blocking buffer). After washing 3 times
with T-TBS, the membrane was incubated overnight at 4 °C with a 1:50
dilution of puriﬁed AG3.0 mAb in blocking buffer. The membrane was
then washed and incubated for 1 h at room temperature with a
1:10,000 dilution of goat anti-mouse IgG peroxidase conjugate (Sigma-
Aldrich). After three ﬁnal washes, spots were visualized using the
410 B.E. Sanders-Beer et al. / Virology 422 (2012) 402–412enhanced chemiluminescence kit (Amersham), followed by exposure to
photographic ﬁlm (RPN 2103H Hyperﬁlm, Amersham).
Antigen capture ELISA
Protein G sepharose column (Pharmacia) 4 Fast Flow (25 ml) was
used to purify IgG from cell culture supernatants according to the
manufacturer's instructions. For the antigen capture ELISA, 50 μl of a
13.5 μg/ml AG3.0 solution in distilled water was dried onto 96-well
ﬂat-bottom polystyrene assay plates (PRO BIND, BD Biosciences)
overnight at 37 °C. The next day, the monoclonal antibody layer was
blocked with 100 μl PBS/2% nonfat milk powder for 1 h and subse-
quently washed 3 times with PBS/0.05% Tween20. SIV/HIV superna-
tant or SIV/HIV infected cells were lysed with 0.2% Tween20 for
30 min., 100 μl lysate plus 50 μl PBS/2% nonfat milk powder/0.05%
Tween20 added to the AG3.0 coated wells, and the plates incubated
overnight at 4 °C and the next day for 2 h at 37 °C. The plates were
washed 3 times with PBS/0.05% Tween20, 50 μl of speciﬁc anti-SIV
plasma from an infected monkey or plasma pool from HIV-1 infected
individuals, diluted 1:1000 in PBS/2% nonfat milk powder/0.05%
Tween20, were added to the wells, and the plates incubated at
37 °C for 1 h. The plates were then washed 5 times with PBS/0.05%
Tween20 and under the stream of tab water for ﬁve seconds. Finally,
10 μg o-phenylenediaminedihydrochloride (Sigma-Aldrich) in 50 μl
PBS pH 6.0 and 0.012 μl H2O2 were added as substrate, and the reac-
tion stopped with 20 μl 2.5 M H2SO4. The optical density of each
well was read at 492 nm using a microplate reader.
Immunostaining of cells
Flat bottom 96-well plates were incubated with 5 μg of poly-L-
lysine (Sigma) in 100 μl of distilled water overnight at 4 °C. Plates
were washed twice with PBS, and 200 μl of cell suspension was
added to the wells. Plates were incubated for 1 h at 37 °C to allow
cells to settle, and then the supernatant was removed. Plates were
submerged in −20 °C methanol and ﬁxed for 30 min. at −20 °C
before carefully washing three times with PBS and blocking with
100 μl of PBS/2% nonfat milk powder for 1 h at room temperature.
The blocking solution was then removed, and 50 μl of the appropri-
ate anti-SIV/HIV plasma diluted in PBS/2% nonfat milk powder
added for 1 h at 37 °C. Wells were washed ﬁve times with PBS and
incubated with 50 μl of 1:500 anti-human IgG (Sigma-Aldrich) in
PBS/2% nonfat milk powder for 1 h at 37 °C. Wells were then washed
again ﬁve times with PBS and ﬁnally the substrate added (10 μg 3-
amino-9-ethylcarbazol (Sigma-Aldrich), 2.5 μl dimethylformamide,
47.5 μl 20 mM sodium acetate, pH 5.0, and 0.025 μl H2O2 per well).
After 10 to 20 min of incubation with the substrate, SIV/HIV infected
cells were stained red. The wells were washed once with PBS, and
the substrate reaction stopped with 20% glycerol.
Virus titrations
To determine the TCID50 of virus stocks, supernatants were initially
diluted 1:10 and then 11 dilutions steps with 1:3 dilutions were
performed. Row 12 served as negative control (medium only). Fifty
microliters of virus dilutions or media were added to 2×103 C8166 or
Molt4clone8 cells in 8 replicates. The plates were incubated for 7 days,
and the SIV/HIV replication was monitored by antigen capture assay
or cellular immunostaining.
Surface plasmon resonance (SPR) analysis
To determine the binding afﬁnity of Gag proteins derived from the
different SIVs to the monoclonal AG3.0 mAb, samples were analyzed
in duplicate with a BIAcore X100 instrument (GE Healthcare) at
25 °C in HBS-EP+buffer (10 mM Hepes, 150 mM NaCl, 3 mM EDTA,0.05% Surfactant P20, pH 7.4) using the mouse antibody capture kit
(GE Healthcare). The ﬁnal immobilization level of anti-mouse IgG
antibody was 8500 RU on both ﬂow cells (Fc1 and Fc2) as recom-
mended by the manufacturer. The antibody was captured at a ﬁnal
concentration of 20 μg/ml for 20 s at a ﬂow rate of 10 μl/min and a
constant level of 500 RU and 120 RU for measuring SIV Gag binding.
The different analytes were injected under the following conditions:
The association/dissociation times for SIVagmVer Gag and SIVmac
Gag were 720/1200 s and for SIVagmSab Gag 1080/5400 s. Further-
more, association and dissociation curves were estimated for all 3
Gag proteins using an injection period of 1080 s and a dissociation
time of 3000 s at a ﬂow rate of 5 μl/min. The regeneration buffer
consisted of 10 mM glycine/HCl, pH 1.7. The apparent kD values
were determined using the BiaEvaluation software (GE Healthcare).
All three Gag preparations (SIVagmVer, SIVagmSab, and SIVmac)
were produced from native puriﬁed virus.
Sequencing of the AG3.0 heavy and light chain variable regions
RNA was isolated from 1×107 AG3.0 hybridoma cells using the
RNeasy plus kit (Qiagen) according to the manufacturer's instructions
and eluted in 30 μl DEPC-treated H2O. cDNA was generated with the
Cloned AMV cDNA synthesis kit (Invitrogen) using oligodT primers
and a temperature of 50 °C for 1 h. Ampliﬁcation of variable region
fragments was performed with 1.25U Pfu DNA polymerase (Fermen-
tas) in the supplied PCR buffer containing 2 mM MgSO4, 0.2 mM
dNTPs, and 25 pmol of each primer per 50 μl reaction. Forward and
reverse primers from a mouse IgG library primer set (Progen) were
used in all possible combinations for light and heavy chain fragments.
Ampliﬁcation cycles were as follows: initial denaturation for 5 min at
95 °C, followed by 35 cycles of 30 s/95 °C, 30 s/55 °C, 60 s/72 °C and a
ﬁnal elongation of 10 min at 72 °C. Ampliﬁed PCR products of approx-
imately 400 kb were puriﬁed using a PCR puriﬁcation kit (Fermentas)
or, if more than one product was generated, separated on a 1.5% aga-
rose gel and subsequently extracted using a gel extraction kit
(Qiagen). Sequencing was performed on an ABI 3500DX sequencer.
Sequences obtained were analyzed using Vbase2 (http://www.
vbase2.org) to identify the complementarity determining regions of
the heavy and light chain variable fragments.
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